Objective: To analyze the phylogeny of the VP1 region of Coxsackie virus A4 (CVA4) from herpangina cases of Shenzhen in 2012 and 2014.
Methods: Real-time reverse transcription(RT)-PCR method was used to test virus such as human enterovirus71, coxsackievirus A16, coxsackievirus A4, coxsackievirus A6 and coxsackievirus A10. The VP1 gene of CVA4 positive samples were amplified by RT-PCR and sequenced. Then the homology and phylogeny analysis of the CVA4 VP1 region was performed.
Results: The six CVA4 isolates identified in the herpangina cases during 2012 and 2014 were mostly closed with GIb genotypes. The nucleotide and amino acid homology between them were 94.1% (nucleotide mutation rate was 5.9%) and 98.3%, five amino acid mutation were found in CVA4 strain 2014 of Shenzhen: aa22N-S, aa34T-A, aa63N-S, aa165A-D, aa200T-A. The phylogenetic analysis based on VP1 region demonstrates that CVA4 strain of Shenzhen in 2012 had the nearest genetic relationship with CVA4 strain of Shandong isolated in 2010 (KF150144). However, CVA4 strain of Shenzhen in 2014 had the nearest genetic relationship with CVA4 strain of Jilin (JQ715709) isolated in 2006.
Conclusions: It reveals that all CVA4 strains from the two outbreak of herpangina belong to genotype GIb, the degree of variation in VP1 region of CVA4 strain of Shenzhen in 2014 is obvious compared with that in 2012.There is an obvious difference on internal trend of evolution lineage between the CVA4 strains from 2012 and 2014.
Download full-text PDF |
Source |
---|
Virol J
December 2024
Wuhan Institute of Biological Products Co., Ltd.,, No.1 Huangjin Industrial Park Road, Jiangxia District, Wuhan, 430207, China.
Background: The hand, foot and mouth disease (HFMD) was caused by species of Enterovirus A and Enterovirus B in the Asian-Pacific region. Broad-spectrum monoclonal antibodies (mAb) that can bind multiple serotypes of enteroviruses have gradually become a research hotspot in the diagnosis, prevention and treatment of HFMD.
Methods: In this study, a mAb 1H4 was obtained using monoclonal antibody technology by immunizing purified virus particles of Coxsackievirus A5 (CV-A5).
Sci Rep
November 2024
Department of Pediatrics, Faculty of Medicine, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand.
JMIR Public Health Surveill
September 2024
School of Public Health, National Defense Medical Center, Taipei, Taiwan.
Zhonghua Liu Xing Bing Xue Za Zhi
July 2024
Institute of Acute Infectious Disease Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Key Laboratory of Enteric Pathogenic Microorganisms, National Health Commission, Nanjing 210009, China.
Pediatr Infect Dis J
September 2024
From the Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!